Showing results (11-20 of 35) with videos related to
Sort By:
Pageof 4
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 15, 2013
Risk of pure red cell aplasia in patients with hepatitis C receiving antiviral therapy and an erythropoiesis-stimulating agentJerome Rossert, Susan Yue, Karen Smirnakis, et al.Blood Reviews|June 28, 2024
Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatmentJohn W Semple, Alexandra Schifferli, Nichola Cooper, et al.Bioanalysis|July 22, 2014
Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impactSuzanna M Tatarewicz, Daniel T Mytych, Marta Starcevic Manning, et al.British Journal of Haematology|April 21, 2020
Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registryDaniel T Mytych, Joseph K Park, June Kim, et al.Pharmacology Research & Perspectives|March 20, 2026
Pharmacokinetic, Safety, and Immunogenicity Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab-AttoVincent Chow, Muhan Zhou, Daniel T Mytych, et al.The British Journal of Dermatology|May 29, 2026
Repeated switching between biosimilar ABP 654 and reference ustekinumab in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded clinical trial to support interchangeabilityAndrew Blauvelt, Jerry Bagel, Andreas Pinter, et al.The British Journal of Dermatology|October 23, 2024
Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeksAndrew Blauvelt, Kim Papp, Mona Trivedi, et al.Journal of Immunological Methods|May 14, 2016
Establishment of the first WHO Erythropoietin antibody reference panel: Report of an international collaborative studyMeenu Wadhwa, Daniel T Mytych, Chris Bird, et al.Journal of Immunological Methods|April 12, 2025
Inhibition of RANKL is critical for accurate assessment of anti-drug antibody incidence to denosumab in clinical studiesMieke Jill Miller, Mark A Kroenke, Troy Barger, et al.Journal for Immunotherapy of Cancer|April 21, 2022
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncologyYanchen Zhou, Hweixian L Penny, Mark A Kroenke, et al.Pageof 4